84 related articles for article (PubMed ID: 29292854)
1. Efficient identification of compounds suppressing protein precipitation via solvent screening using serial deletion mutants of the target protein.
Yunoki K; Yoshinaga S; Takeda M; Nagano R; Tsuchiya Y; Sonoda A; Tsuji T; Hirakane M; Toda E; Terashima Y; Matsushima K; Terasawa H
Genes Cells; 2018 Feb; 23(2):70-79. PubMed ID: 29292854
[TBL] [Abstract][Full Text] [Related]
2. Rational Design of Monodispersed Mutants of Proteins by Identifying Aggregation Contact Sites Using Solubilizing Agents.
Tsuji T; Yoshinaga S; Takeda M; Sato T; Sonoda A; Ishida N; Yunoki K; Toda E; Terashima Y; Matsushima K; Terasawa H
Biochemistry; 2020 Oct; 59(39):3639-3649. PubMed ID: 32929969
[TBL] [Abstract][Full Text] [Related]
3. Identification of a binding element for the cytoplasmic regulator FROUNT in the membrane-proximal C-terminal region of chemokine receptors CCR2 and CCR5.
Toda E; Terashima Y; Esaki K; Yoshinaga S; Sugihara M; Kofuku Y; Shimada I; Suwa M; Kanegasaki S; Terasawa H; Matsushima K
Biochem J; 2014 Jan; 457(2):313-22. PubMed ID: 24128342
[TBL] [Abstract][Full Text] [Related]
4. FROUNT is a common regulator of CCR2 and CCR5 signaling to control directional migration.
Toda E; Terashima Y; Sato T; Hirose K; Kanegasaki S; Matsushima K
J Immunol; 2009 Nov; 183(10):6387-94. PubMed ID: 19841162
[TBL] [Abstract][Full Text] [Related]
5. Identification and Preparation of a Novel Chemokine Receptor-Binding Domain in the Cytoplasmic Regulator FROUNT.
Sonoda A; Yoshinaga S; Yunoki K; Ezaki S; Yano K; Takeda M; Toda E; Terashima Y; Matsushima K; Terasawa H
Mol Biotechnol; 2017 May; 59(4-5):141-150. PubMed ID: 28342149
[TBL] [Abstract][Full Text] [Related]
6. Expression and purification of human FROUNT, a common cytosolic regulator of CCR2 and CCR5.
Esaki K; Terashima Y; Toda E; Yoshinaga S; Araki N; Matsushima K; Terasawa H
Protein Expr Purif; 2011 May; 77(1):86-91. PubMed ID: 21193048
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the binding of the membrane-proximal C-terminal region of chemokine receptor CCR2 with the cytosolic regulator FROUNT.
Esaki K; Yoshinaga S; Tsuji T; Toda E; Terashima Y; Saitoh T; Kohda D; Kohno T; Osawa M; Ueda T; Shimada I; Matsushima K; Terasawa H
FEBS J; 2014 Dec; 281(24):5552-66. PubMed ID: 25283965
[TBL] [Abstract][Full Text] [Related]
8.
Yoshinaga S; Ishida N; Tsuji T; Sonoda A; Yunoki K; Takeda M; Toda E; Terashima Y; Matsushima K; Terasawa H
Biomol NMR Assign; 2018 Oct; 12(2):259-262. PubMed ID: 29594928
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl amino acid amide solubility in aqueous 1,6-hexanediol solutions: Insights into the protein droplet deformation mechanism.
Hirano A; Wada M; Sato TK; Kameda T
Int J Biol Macromol; 2024 Mar; 261(Pt 1):129724. PubMed ID: 38272403
[TBL] [Abstract][Full Text] [Related]
10. Aqueous solvent system for the solubilization of azole compounds.
Kovács K; Stampf G; Klebovich I; Antal I; Ludányi K
Eur J Pharm Sci; 2009 Feb; 36(2-3):352-8. PubMed ID: 19022381
[TBL] [Abstract][Full Text] [Related]
11. Insights into CC Chemokine Ligand 2/Chemokine Receptor 2 Molecular Recognition: A Step Forward toward Antichemotactic Agents.
David KS; Oliveira ERA; Horta BAC; Valente AP; de Paula VS
Biochemistry; 2017 Jun; 56(25):3197-3210. PubMed ID: 28570817
[TBL] [Abstract][Full Text] [Related]
12. High throughput screening: an in silico solubility parameter approach for lipids and solvents in SLN preparations.
Shah M; Agrawal Y
Pharm Dev Technol; 2013; 18(3):582-90. PubMed ID: 22107345
[TBL] [Abstract][Full Text] [Related]
13. A Novel Saccharomyces cerevisiae FG Nucleoporin Mutant Collection for Use in Nuclear Pore Complex Functional Experiments.
Adams RL; Terry LJ; Wente SR
G3 (Bethesda); 2015 Nov; 6(1):51-8. PubMed ID: 26530420
[TBL] [Abstract][Full Text] [Related]
14. High-throughput 96-well solvent mediated sonic blending synthesis and on-plate solid/solution stability characterization of pharmaceutical cocrystals.
Luu V; Jona J; Stanton MK; Peterson ML; Morrison HG; Nagapudi K; Tan H
Int J Pharm; 2013 Jan; 441(1-2):356-64. PubMed ID: 23178596
[TBL] [Abstract][Full Text] [Related]
15. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing.
Mansky P; Dai WG; Li S; Pollock-Dove C; Daehne K; Dong L; Eichenbaum G
J Pharm Sci; 2007 Jun; 96(6):1548-63. PubMed ID: 17094139
[TBL] [Abstract][Full Text] [Related]
16. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing.
Shanbhag A; Rabel S; Nauka E; Casadevall G; Shivanand P; Eichenbaum G; Mansky P
Int J Pharm; 2008 Mar; 351(1-2):209-18. PubMed ID: 18054181
[TBL] [Abstract][Full Text] [Related]
17. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
Li S; Pollock-Dove C; Dong LC; Chen J; Creasey AA; Dai WG
Mol Pharm; 2012 May; 9(5):1100-8. PubMed ID: 22376012
[TBL] [Abstract][Full Text] [Related]
18. Effect of nicotinamide and urea on the solubility of riboflavin in various solvents.
Coffman RE; Kildsig DO
J Pharm Sci; 1996 Sep; 85(9):951-4. PubMed ID: 8877885
[TBL] [Abstract][Full Text] [Related]
19. Mutational analyses of the extracellular domain of the full-length lutropin/choriogonadotropin receptor suggest leucine-rich repeats 1-6 are involved in hormone binding.
Thomas D; Rozell TG; Liu X; Segaloff DL
Mol Endocrinol; 1996 Jun; 10(6):760-8. PubMed ID: 8776736
[TBL] [Abstract][Full Text] [Related]
20. Solubility enhancement of Cox-2 inhibitors using various solvent systems.
Seedher N; Bhatia S
AAPS PharmSciTech; 2003; 4(3):E33. PubMed ID: 14621965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
